VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CVS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CVSCVS Health Corporation
$104.33$133.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCVSFinancials

CVS Health Corporation (CVS) Financials

30Y historyFree accessUpdated daily

Revenue grew 6.2% year-over-year to $100.4B in 2026Q1, yet structural margin compression persists as evidenced by a 4.7% operating margin.

CVS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue407.9B402.07B372.81B357.78B322.47B292.11B268.71B256.78B194.58B184.79B177.55B153.29B139.37B126.76B123.12B107.08B95.78B98.22B87.47B76.33B43.82B37.01B30.59B26.59B24.18B22.24B20.09B18.1B15.27B13.75B11.83B
Revenue Growth %7.64%7.85%4.2%10.95%10.39%8.71%4.65%31.96%5.3%4.08%15.82%9.99%9.94%2.96%14.98%11.8%-2.48%12.28%14.6%74.18%18.41%20.96%15.07%9.95%8.72%10.72%10.99%18.49%11.08%16.21%21.18%
Cost of Goods Sold0------------------------------
COGS % of Revenue-------------------------------
Gross Profit56.59B55.36B51.4B54.43B54.5B52.12B49.05B45.53B31.54B28.53B28.83B26.53B25.37B23.78B22.49B20.56B20.22B20.36B18.29B16.11B11.74B9.69B8.03B6.86B6.07B5.69B5.36B4.86B4.13B3.72B3.36B
Gross Margin %13.87%13.77%13.79%15.21%16.9%17.84%18.25%17.73%16.21%15.44%16.24%17.31%18.2%18.76%18.27%19.2%21.11%20.73%20.91%21.1%26.8%26.2%26.25%25.81%25.1%25.59%26.69%26.86%27.03%27.07%28.38%
Gross Profit Growth %-7.71%-5.57%-0.13%4.57%6.27%7.73%44.36%10.55%-1.06%8.69%4.58%6.66%5.76%9.37%1.7%-0.68%11.31%13.55%37.18%21.12%20.71%17.02%13.09%6.64%6.14%10.29%17.73%10.92%10.85%15.64%
Operating Expenses50.62B44.98B42.88B40.69B46.55B38.81B35.13B33.54B27.52B18.99B18.45B17.05B16.57B15.75B15.28B14.23B14.08B13.93B12.24B11.31B9.3B7.68B6.58B5.44B4.86B4.92B4.04B3.73B3.2B3.02B2.75B
OpEx % of Revenue-11.19%11.5%11.37%14.44%13.29%13.08%13.06%14.14%10.28%10.39%11.12%11.89%12.42%12.41%13.29%14.7%14.19%14%14.82%21.22%20.74%21.5%20.46%20.11%22.12%20.11%20.59%20.94%21.95%23.27%
Selling, General & Admin0041.23B00000000000014.23B14.09B13.93B12.24B11.31B9.3B7.68B6.08B5.1B4.55B4.25B3.74B3.45B2.95B2.78B2.49B
SG&A % of Revenue--11.06%------------13.29%14.71%14.19%14%14.82%21.22%20.74%19.87%19.17%18.83%19.1%18.63%19.05%19.31%20.19%21.05%
Research & Development0------------------------------
R&D % of Revenue-------------------------------
Other Operating Expenses0------------------------------
Operating Income5.97B10.38B8.52B13.74B7.95B13.31B13.91B11.99B4.02B9.54B10.39B9.47B8.8B8.04B7.21B6.33B6.14B6.42B6.05B4.79B2.44B2.02B1.45B1.42B1.21B770.6M1.32B1.14B930.5M704.1M604.7M
Operating Margin %1.46%2.58%2.28%3.84%2.47%4.56%5.18%4.67%2.07%5.16%5.85%6.18%6.31%6.34%5.86%5.91%6.41%6.54%6.91%6.28%5.57%5.46%4.75%5.35%4.99%3.46%6.58%6.27%6.09%5.12%5.11%
Operating Income Growth %-21.95%-38.03%72.78%-40.24%-4.32%16.05%198.11%-57.84%-8.16%9.61%7.68%9.48%11.47%13.88%3.16%-4.48%6.27%26.13%96.32%20.9%38.83%2.18%18.02%56.53%-41.74%16.49%22.03%32.15%16.44%52.62%
EBITDA10.53B14.99B13.11B18.11B12.18B17.8B18.35B16.36B6.74B12.02B12.86B11.57B10.73B9.91B8.96B7.9B7.61B7.81B7.32B5.89B3.17B2.61B1.89B1.77B1.52B1.09B1.62B1.41B1.18B946.7M867.5M
EBITDA Margin %2.58%3.73%3.52%5.06%3.78%6.09%6.83%6.37%3.46%6.5%7.24%7.55%7.7%7.82%7.28%7.38%7.94%7.96%8.37%7.71%7.25%7.05%6.19%6.64%6.27%4.91%8.06%7.81%7.73%6.89%7.33%
EBITDA Growth %-25.99%14.32%-27.59%48.7%-31.57%-3.03%12.19%142.74%-43.92%-6.56%11.19%7.8%8.31%10.53%13.47%3.85%-2.66%6.75%24.32%85.45%21.71%37.69%7.32%16.41%38.95%-32.6%14.57%19.76%24.66%9.13%19.84%
D&A (Non-Cash Add-back)4.57B4.61B4.6B4.37B4.22B4.49B4.44B4.37B2.72B2.48B2.48B2.09B1.93B1.87B1.75B1.57B1.47B1.39B1.27B1.09B733.3M589.1M439.9M341.7M310.3M320.8M296.6M277.9M249.7M242.6M262.8M
EBIT6.57B5.25B9.11B13.83B8.12B13.04B12.68B12.03B4.03B9.33B9.71B9.47B8.29B8.04B6.87B6.33B6.14B6.43B6.07B4.79B2.44B2.02B1.45B1.42B1.21B1.12B1.32B1.14B930.5M704.1M604.7M
Net Interest Income-3.11B-3.12B-2.96B-2.66B-2.29B-2.5B-2.91B-3.04B-2.62B-1.06B-1.06B-838M-600M-509M-557M-584M-536M-525M-509M000000000000
Interest Income000000000020M21M15M8M4M4M3M5M21M000000000000
Interest Expense3.11B3.12B2.96B2.66B2.29B2.5B2.91B3.04B2.62B1.06B1.08B859M615M517M561M588M539M530M530M000000000000
Other Income/Expense0------------------------------
Pretax Income3.46B2.14B6.15B11.17B5.84B10.54B9.77B9B1.41B8.27B8.64B8.62B7.68B7.53B6.3B5.75B5.6B5.9B5.54B4.36B2.23B1.91B1.4B1.38B1.16B709.6M1.24B1.08B691M237.6M643.4M
Pretax Margin %0.85%0.53%1.65%3.12%1.81%3.61%3.64%3.5%0.72%4.47%4.86%5.62%5.51%5.94%5.12%5.37%5.85%6.01%6.33%5.71%5.08%5.16%4.56%5.17%4.78%3.19%6.19%5.95%4.52%1.73%5.44%
Income Tax568M408M1.56B2.81B1.51B2.55B2.57B2.37B2B1.64B3.32B3.39B3.03B2.93B2.44B2.26B2.18B2.2B2.19B1.72B856.9M684.3M477.6M528.2M439.2M296.4M497.4M441.3M306.5M149.2M271M
Effective Tax Rate %16.43%19.1%25.41%25.11%25.86%24.18%26.29%26.3%142.39%19.8%38.4%39.3%39.5%38.89%38.64%39.29%38.9%37.29%39.61%39.5%38.5%35.85%34.2%38.4%38%41.77%40%41%44.36%62.79%42.12%
Net Income2.93B1.77B4.61B8.34B4.31B8B7.18B6.63B-594M6.62B5.32B5.24B4.64B4.59B3.86B3.46B3.43B3.7B3.21B2.64B1.37B1.22B918.8M847.3M716.6M413.2M746M635.1M384.5M88.8M208.2M
Net Margin %0.72%0.44%1.24%2.33%1.34%2.74%2.67%2.58%-0.31%3.58%2.99%3.42%3.33%3.62%3.14%3.23%3.58%3.76%3.67%3.45%3.12%3.31%3%3.19%2.96%1.86%3.71%3.51%2.52%0.65%1.76%
Net Income Growth %-44.47%-61.68%-44.7%93.55%-46.12%11.45%8.22%1216.84%-108.97%24.54%1.53%12.77%1.13%18.84%11.61%1.02%-7.28%15.07%21.81%92.64%11.77%33.29%8.44%18.24%73.43%-44.61%17.46%65.18%333%-57.35%136.35%
Net Income (Continuing)2.89B1.73B4.59B8.37B4.33B7.99B7.2B6.63B-596M6.63B5.32B5.23B4.64B4.6B3.87B3.49B3.42B3.71B3.34B2.64B1.37B1.22B918.8M847.3M716.6M413.2M746M635.1M384.5M88.4M372.4M
Discontinued Operations000000-9M00009M0000-15M00000000000000
Minority Interest181M168M170M175M300M306M312M306M318M4M4M7M5M0030M34M00000000000000
EPS (Diluted)2.291.393.666.473.265.955.465.08-0.576.444.904.633.963.743.032.572.492.552.181.921.601.451.101.030.880.500.920.780.480.100.26
EPS Growth %-45.81%-62.02%-43.43%98.47%-45.21%8.97%7.48%991.23%-108.85%31.43%5.83%16.92%5.88%23.43%17.9%3.21%-2.35%16.97%13.54%20%10.34%31.82%6.8%17.05%76%-45.65%17.95%62.5%405.26%-63.46%117.11%
EPS (Basic)-1.403.666.493.296.005.485.10-0.576.474.934.663.983.773.052.592.512.582.231.971.651.491.131.060.900.510.940.800.480.100.27
Diluted Shares Outstanding1.28B1.27B1.26B1.29B1.32B1.33B1.31B1.3B1.04B1.02B1.08B1.13B1.17B1.23B1.28B1.35B1.38B1.45B1.47B1.37B853.2M841.6M822.36M808.45M810.6M797M799.34M817.8M810.4M790.53M426.4M
Basic Shares Outstanding1.27B1.27B1.26B1.28B1.31B1.32B1.31B1.3B1.04B1.02B1.07B1.12B1.16B1.22B1.27B1.34B1.37B1.43B1.43B1.33B820.6M811.4M800.53M785.57M784.6M781.37M782.25M782.6M774.2M751M426.4M
Dividend Payout Ratio-192.14%73.1%37.54%67.43%32.81%36.55%39.24%-30.94%34.61%30.09%27.73%23.89%21.45%19.47%13.98%--------------

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Medicare Advantage utilization volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Amidst Segment Shifts

According to reported financial data, CVS sustained a consistent revenue growth trajectory, with quarterly figures reaching $100.4B in 2026Q1, reflecting a 6.2% year-over-year increase that highlights the firm's ability to maintain top-line momentum despite significant headwinds in its core insurance and pharmacy services segments.

The revenue expansion appears driven by the recurring nature of the Health Care Benefits and Pharmacy Services segments, which provide a stable foundation for the enterprise. However, investors should monitor whether this growth is sustainable given the competitive pressures in the retail pharmacy space and the potential for regulatory changes to impact PBM revenue recognition.

Structural Margin Compression Remains Evident

As indicated by the latest income statement filings, CVS's gross margin fluctuated to 15.6% in 2026Q1, a figure that underscores the inherent difficulty in maintaining profitability within a vertically integrated model facing elevated medical utilization rates and intense pricing pressure across its diverse healthcare delivery platforms.

The thin net margin profile suggests that the company's integrated model is currently struggling to capture the anticipated synergies between its insurance and retail arms. This contraction warrants further investigation into whether the current margin levels represent a cyclical trough or a more permanent shift in the profitability of Medicare Advantage plans.

Operating Leverage Constrained by Costs

Based on the provided quarterly data, CVS's operating income has shown significant volatility, swinging from a $3.2B loss in 2025Q3 to $4.7B in 2026Q1, which suggests that the company's ability to scale operating profit faster than gross profit remains highly sensitive to unpredictable medical benefit ratios.

The lack of consistent operating leverage implies that the firm's cost structure is heavily burdened by the integration of primary care acquisitions and rising clinical expenses. Analysts should scrutinize whether management can achieve greater overhead efficiency as these recent investments mature and move past the initial integration phase.

Sustainability of Earnings Quality Challenged

Financial statements reveal that CVS's net income is subject to significant quarterly variance, with EPS dropping to a loss of $3.13 in 2025Q3 before recovering to $2.30 in 2026Q1, a pattern that raises questions regarding the underlying quality and predictability of the company's reported earnings.

The reliance on non-operating adjustments and the impact of prior-year reserve developments in the insurance segment may mask the true operational performance of the business. Investors should remain cautious, as the high level of goodwill on the balance sheet could lead to future impairment charges if the primary care strategy fails to deliver expected returns.

CVS — Frequently Asked Questions

Quick answers to the most common questions about buying CVS stock.

What was CVS Health Corporation's (CVS) revenue in 2025?

For fiscal year 2025, CVS Health Corporation (CVS) reported total revenue of $402.07B. This represents a 3298.2% increase compared to $11.83B in 1996.

Is CVS Health Corporation (CVS) profitable?

CVS Health Corporation (CVS) is profitable, generating $1.77B in net income for the fiscal year ending 2025 with a net profit margin of 0.4%.

What is CVS Health Corporation's operating profit margin?

CVS Health Corporation (CVS) reported an operating income of $10.38B, resulting in an operating profit margin of 2.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is CVS Health Corporation's gross profit and gross margin?

CVS Health Corporation (CVS) generated $55.36B in gross profit for the year, representing a gross profit margin of 13.8%. This demonstrates the company's core pricing power and production efficiency.